Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

LEAD enters deal with ShangPharma
December 2007
SHARING OPTIONS:

SAN BRUNO, Calif.-LEAD Therapeutics Inc., a chemistry-driven drug discovery company based in the San Francisco Bay Area, recently announced it has entered into a strategic research collaboration with Shanghai ChemPartner in China, the wholly owned subsidiary of ShangPharma. In conjunction with this collaboration, China Gateway Life Science (Holding) Ltd., the strategic investment arm of ShangPharma, has made an equity investment in LEAD Therapeutics.
 Under the terms of this strategic collaboration, LEAD Therapeutics will have access to a dedicated team of scientists at ChemPartner, with operational flexibility and significant room for expansion. A joint steering committee has been appointed to oversee the objectives and progress of the collaboration.
 "This creative relationship with one of the leading discovery contract research organizations in China will greatly accelerate our drug discovery efforts towards generating novel and differentiated pre-IND candidates," says Dr. Peter Myers, CEO and chairman of the board of LEAD Therapeutics. "This is one of the ways that LEAD Therapeutics is differentiating itself in effectively and rapidly leveraging China's technical capabilities in the life science arena."
 "We are pleased to establish this strategic relationship with LEAD Therapeutics, an innovative drug discovery company in the United States," said ShangPharma CEO Michael Hui. "Our collaboration with LEAD represents one of the many ways that we hope to participate in the dynamic biotech industry and contribute to its growth."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.